AstraZeneca Deserves $76M In Drug Patent Suit, Judge Says

Law360, Los Angeles (December 3, 2013, 6:26 PM EST) -- AstraZeneca AB has successfully demonstrated that it is entitled to more than $76 million for Canada-based Apotex Corp. and Torpharm Inc.’s infringement of patents that protected the company's indigestion drug Prilosec, according to a New York federal judge’s ruling unsealed Tuesday.

The suit is the last of several similar infringement actions consolidated in the same court concerning generic omeprazole, known by its brand name Prilosec. Apotex sold its generic omeprazole starting November 2003 until 2007, when it was found to have infringed Astra's patents, according to court documents....
To view the full article, register now.